Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$77.10 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.15M
Market Cap
$5.23B
Enterprise ValueN/A
Total Cash (Recent Filing)$298.70M
Total Debt (Recent Filing)$105.48M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Jul 30, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding57,140,526
10 Day Avg. Volume1,321,596
30 Day Avg. Volume1,150,977
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)6.44
Price to Sales (P/S)0.00
P/FCF Ratio-93.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$124.09Price Target Upside35.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
EarningsFirst-quarter sales were above Street estimates, driven primarily by iDose and international glaucoma.
Product PerformanceIDose sales nearly doubled in 4Q to ~$15.5M and are expected to reach $100M+ in FY25, indicating strong growth potential for this product.
Reimbursement ProgressNoridian is making significant progress in terms of iDose reimbursement, consistently processing claims within 11-20 days.
Bears Say
Market ConcernsShares of Glaukos Corp. experienced a decline due to concerns about the 2025 US iDose outlook, particularly related to local coverage determinations affecting the core US MIGS franchise.
Regulatory ChallengesChallenges with Novitas have led to some iDose procedure halts due to delays in facility fee payments, although this has been resolved for some but remains an issue for others.
Regulatory ImpactRecent changes in Local Coverage Determinations (LCD) for core MIGS are expected to negatively impact business performance until existing challenges are overcome.
---
Ownership Overview
5.95% Insiders
41.16% Mutual Funds
0.09% Other Institutional Investors
28.39% Public Companies and
Individual Investors
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $77.10 and its highest was $163.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $5.23B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Jul 30, 2025 which is in 75 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Apr 30, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.128.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.26.
How many shares outstanding does Glaukos have?
Glaukos has 57,140,526 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went down -11.363%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
---
Glaukos Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$124.09 (35.44% Upside)
$124.09 (35.44% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 22.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.74%
12-Months-Change
Fundamentals
Return on Equity
-20.36%
Trailing 12-Months
Asset Growth
3.52%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
---
GKOS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Glaukos demonstrated strong financial performance with record revenues and robust growth in the iDose TR and international glaucoma franchises. However, challenges such as the impact of LCD restrictions on the U.S. stent business and Photrexa revenue impact were noted. Despite these challenges, the company maintains a strong financial position and continues to advance promising pipeline products.Read More>---
GKOS Stock 12 Month Forecast
Average Price Target
$124.09
▲(35.44% Upside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
Inspire Medical Systems
―
PROCEPT BioRobotics
―
---